Влияние пола на развитие вторичной неэффективности генно-инженерных биологических препаратов у био-наивных пациентов с псориатическим артритом

Abstract

Currently, the problem of psoriatic arthritis is very relevant and attracts the attention of researchers from the standpoint of studying the factors associated with all aspects of this disease, including the effectiveness of the therapy. The present study was aimed at studying the possibility of the influence of sex on the development of secondary failure of genetically engineered biological drugs in bio-naive patients with psoriatic arthritis. According to the results obtained, among patients receiving genetically engineered biological therapy, the period of development of secondary failure of the first-line genetically engineered biological drug was higher in women. The revealed pattern differs from the results obtained when comparing the survival of genetically engineered biological therapy in general in men and women with psoriatic arthritis but correlates with data on sex differences in the course and manifestations of the disease. Thus, the results of the study suggest the influence of sex on the development of secondary failure of genetically engineered biological drugs in patients with psoriatic arthritis, which necessitates further research in this direction with greater selectivity.